Midatech Pharma PLC (“Midatech”, the “Company” or the “Group”) Pre-Close Trading Update
January 06, 2016 02:00 ET | Midatech Pharma PLC
OXFORD, United Kingdom, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising...
Commence Bio Finalizes Corporate Identity Change From WibiWorks Therapeutics and Introduces New Website
January 04, 2016 14:54 ET | Commence Bio
SPARKS, MD--(Marketwired - January 04, 2016) - Reflecting the STaRT™ of something big in immunotherapy, Commence Bio, Inc. today announced the completion of its corporate name change transition...
Agios Pharmaceuticals logo
Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
January 04, 2016 08:16 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
December 17, 2015 11:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
Poseida.jpg
Poseida Therapeutics Announces Series A Financing
December 16, 2015 09:00 ET | Poseida Therapeutics, Inc.
LA JOLLA, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a US-based, privately-held, human therapeutics company focused on the development of novel therapies using...
Nemucore Medical Innovations Announces Licensing Agreement With Pfenex Inc. Enabling Manufacture of Anti-Cancer Therapeutic NMI-8000, the Biologically Active Form of Mullerian Inhibitory Substance (MIS)
December 14, 2015 08:05 ET | Nemucore Medical Innovations, Inc.
WORCESTER, Mass., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
December 10, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
  --Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New...
CollabRx, Inc. Logo
CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016
December 10, 2015 07:00 ET | CollabRx, Inc.
SAN FRANCISCO, Dec. 10, 2015 (GLOBE NEWSWIRE) -- CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced that its...
Nemucore Medical Innovations Announces Appointment of Dr. Michael V. Seiden to Its Board of Directors and Clinical Advisory Board
December 09, 2015 08:05 ET | Nemucore Medical Innovations, Inc.
WORCESTER, Mass., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 07, 2015 16:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...